SGLT2 inhibitors had a similar effect in HbA1C (T1DM −1.30% [−2.35, −0.26] vs T2DM −1.23% [−3.19, −0.72]), FPG (T1DM −2.47 mmol/L [−3.65, −1.28] vs T2DM −0.50 mmol/L [1.60, 0.60]), insulin dose (T1DM −7.27 U/24 hours [−19.82, 5.28] vs T2DM −7.02 U/24 hours [−15.33, 1.30]), and body weight (T1DM −1.30 kg [−2.35, −0.26] vs T2DM −2.53 kg [−3.10, −1.56]) with T1DM and T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.